高迁移率族蛋白 B1 衍生肽作为佐剂诱导对肽和蛋白抗原的免疫应答。
HMGB1-derived peptide acts as adjuvant inducing immune responses to peptide and protein antigen.
机构信息
Rebecca and John Moores Cancer Center, University of California San Diego (UCSD), La Jolla, CA 92093, USA.
出版信息
Vaccine. 2010 Nov 3;28(47):7556-62. doi: 10.1016/j.vaccine.2010.08.054. Epub 2010 Aug 25.
Abstract
There is a need for new adjuvants that will induce immune responses to subunit vaccines. We show that a short peptide, named Hp91, whose sequence corresponds to an area within the endogenous molecule high mobility group box (HMGB1) protein 1 potentiates cellular immune responses to peptide antigen and cellular and humoral immune responses to protein antigen in vivo. Hp91 promoted the in vivo production of the immunomodulatory cytokines, IFN-γ, TNF-α, IL-6, and IL-12 (p70), as well as antigen-specific activation of CD8+ T cells. These results demonstrate the ability of a short immunostimulatory peptide to serve as an adjuvant for subunit vaccines.
摘要
需要新的佐剂来诱导亚单位疫苗的免疫反应。我们发现，一种名为 Hp91 的短肽，其序列对应于内源性分子高迁移率族蛋白 1（HMGB1）蛋白 1 内的一个区域，可增强体内对肽抗原的细胞免疫反应以及对蛋白抗原的细胞和体液免疫反应。Hp91 促进了免疫调节细胞因子 IFN-γ、TNF-α、IL-6 和 IL-12（p70）的体内产生，以及抗原特异性 CD8+T 细胞的激活。这些结果表明，一种短的免疫刺激性肽能够作为亚单位疫苗的佐剂。
相似文献
1
HMGB1-derived peptide acts as adjuvant inducing immune responses to peptide and protein antigen.高迁移率族蛋白 B1 衍生肽作为佐剂诱导对肽和蛋白抗原的免疫应答。
Vaccine. 2010 Nov 3;28(47):7556-62. doi: 10.1016/j.vaccine.2010.08.054. Epub 2010 Aug 25.
2
Immuno-Stimulating Peptide Derived from HMGB1 is More Effective Than the N-Terminal Domain of Gp96 as an Endogenous Adjuvant for Improvement of Protein Vaccines.源自HMGB1的免疫刺激肽作为内源性佐剂用于改善蛋白疫苗时比Gp96的N端结构域更有效。
Protein Pept Lett. 2017;24(3):190-196. doi: 10.2174/0929866523666161220111833.
3
Activity of the HMGB1-derived immunostimulatory peptide Hp91 resides in the helical C-terminal portion and is enhanced by dimerization.HMGB1 衍生免疫刺激性肽 Hp91 的活性位于螺旋状的 C 端部分，并通过二聚化增强。
Mol Immunol. 2014 Feb;57(2):191-9. doi: 10.1016/j.molimm.2013.09.007. Epub 2013 Oct 26.
4
TLR4-dependent activation of dendritic cells by an HMGB1-derived peptide adjuvant.由HMGB1衍生肽佐剂介导的树突状细胞的TLR4依赖性激活。
J Transl Med. 2014 Aug 14;12:211. doi: 10.1186/1479-5876-12-211.
5
Co-immunization with an optimized plasmid-encoded immune stimulatory interleukin, high-mobility group box 1 protein, results in enhanced interferon-gamma secretion by antigen-specific CD8 T cells.共免疫优化的质粒编码免疫刺激细胞因子白细胞介素，高迁移率族蛋白 1 结果增强抗原特异性 CD8 T 细胞分泌干扰素-γ。
Immunology. 2009 Sep;128(1 Suppl):e612-20. doi: 10.1111/j.1365-2567.2009.03044.x. Epub 2009 Jan 12.
6
Small heat shock protein 27: An effective adjuvant for enhancement of HIV-1 Nef antigen-specific immunity.小热休克蛋白27：增强HIV-1 Nef抗原特异性免疫的有效佐剂。
Immunol Lett. 2017 Nov;191:16-22. doi: 10.1016/j.imlet.2017.09.005. Epub 2017 Sep 14.
7
Synergistic effect of dual targeting vaccine adjuvant with aminated β-glucan and CpG-oligodeoxynucleotides for both humoral and cellular immune responses.氨基化β-葡聚糖与 CpG-寡脱氧核苷酸联合靶向疫苗佐剂对体液和细胞免疫应答的协同作用。
Acta Biomater. 2018 Sep 15;78:211-223. doi: 10.1016/j.actbio.2018.08.002. Epub 2018 Aug 9.
8
Development of HCV Therapeutic Vaccines Using Hp91 Peptide and Small Heat Shock Protein 20 as an Adjuvant.使用Hp91肽和小热休克蛋白20作为佐剂开发丙型肝炎病毒治疗性疫苗。
Protein Pept Lett. 2018;25(10):924-932. doi: 10.2174/0929866525666180925145304.
9
Hp91 immunoadjuvant: An HMGB1-derived peptide for development of therapeutic HPV vaccines.Hp91免疫佐剂：一种用于开发治疗性人乳头瘤病毒疫苗的源自高迁移率族蛋白B1的肽。
Biomed Pharmacother. 2017 Jan;85:148-154. doi: 10.1016/j.biopha.2016.11.115. Epub 2016 Dec 5.
10
Biotin Functionalized Self-Assembled Peptide Nanofiber as an Adjuvant for Immunomodulatory Response.生物素功能化自组装肽纳米纤维作为免疫调节反应的佐剂。
Biotechnol J. 2020 Dec;15(12):e2000100. doi: 10.1002/biot.202000100. Epub 2020 Jul 26.
引用本文的文献
1
Immunogenic Cell Death, DAMPs and Prothymosin α as a Putative Anticancer Immune Response Biomarker.免疫原性细胞死亡、损伤相关分子模式与胸腺素α原作为一种潜在的抗癌免疫反应生物标志物
Cells. 2022 Apr 22;11(9):1415. doi: 10.3390/cells11091415.
2
Non-thermal plasma modulates cellular markers associated with immunogenicity in a model of latent HIV-1 infection.非热等离子体调节潜伏 HIV-1 感染模型中与免疫原性相关的细胞标志物。
PLoS One. 2021 Mar 1;16(3):e0247125. doi: 10.1371/journal.pone.0247125. eCollection 2021.
3
Aggregation by peptide conjugation rescues poor immunogenicity of the HA stem.通过肽缀合聚集挽救了 HA 茎的免疫原性差的问题。
PLoS One. 2020 Nov 2;15(11):e0241649. doi: 10.1371/journal.pone.0241649. eCollection 2020.
4
Triggered Immune Response Induced by Antigenic Epitopes Covalently Linked with Immunoadjuvant-Pulsed Dendritic Cells as a Promising Cancer Vaccine.抗原表位共价连接免疫佐剂脉冲树突状细胞引发的免疫应答作为一种有前途的癌症疫苗。
J Immunol Res. 2020 Apr 4;2020:3965061. doi: 10.1155/2020/3965061. eCollection 2020.
5
Enhancing the Immune Response of a Nicotine Vaccine with Synthetic Small "Non-Natural" Peptides.增强尼古丁疫苗的免疫反应：合成小分子“非天然”肽的作用。
Molecules. 2020 Mar 12;25(6):1290. doi: 10.3390/molecules25061290.
6
Ovalbumin Epitope SIINFEKL Self-Assembles into a Supramolecular Hydrogel.卵清蛋白表位 SIINFEKL 自组装成超分子水凝胶。
Sci Rep. 2019 Feb 25;9(1):2696. doi: 10.1038/s41598-019-39148-8.
7
Significance of serum antibodies against HPV E7, Hsp27, Hsp20 and Hp91 in Iranian HPV-exposed women.伊朗 HPV 暴露女性血清 HPV E7、Hsp27、Hsp20 和 Hp91 抗体的意义。
BMC Infect Dis. 2019 Feb 12;19(1):142. doi: 10.1186/s12879-019-3780-2.
8
Engineering of a self-adjuvanted iTEP-delivered CTL vaccine.一种自我佐剂化的经iTEP递送的CTL疫苗的工程设计。
Acta Pharmacol Sin. 2017 Jun;38(6):914-923. doi: 10.1038/aps.2017.31. Epub 2017 Apr 17.
9
Tumor-derived factors modulating dendritic cell function.调节树突状细胞功能的肿瘤衍生因子。
Cancer Immunol Immunother. 2016 Jul;65(7):821-33. doi: 10.1007/s00262-016-1820-y. Epub 2016 Mar 16.
10
Adjuvants in the Driver's Seat: How Magnitude, Type, Fine Specificity and Longevity of Immune Responses Are Driven by Distinct Classes of Immune Potentiators.掌控全局的佐剂：不同类型的免疫增强剂如何驱动免疫反应的强度、类型、精细特异性和持久性
Vaccines (Basel). 2014 Apr 10;2(2):252-96. doi: 10.3390/vaccines2020252.
本文引用的文献
1
Delivery of a peptide via poly(D,L-lactic-co-glycolic) acid nanoparticles enhances its dendritic cell-stimulatory capacity.通过聚（D，L-丙交酯-共-乙交酯）纳米粒递呈多肽可增强其树突状细胞刺激能力。
Nanomedicine. 2010 Oct;6(5):651-61. doi: 10.1016/j.nano.2010.03.001. Epub 2010 Mar 27.
2
Role of toll-like receptors 2 and 4, and the receptor for advanced glycation end products in high-mobility group box 1-induced inflammation in vivo.Toll样受体2和4以及晚期糖基化终产物受体在高迁移率族蛋白B1诱导的体内炎症中的作用。
Shock. 2009 Mar;31(3):280-4. doi: 10.1097/SHK.0b013e318186262d.
3
Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer.氨普立生：一种用于癌症免疫治疗的潜在Toll样受体3佐剂。
Vaccine. 2009 May 26;27(25-26):3401-4. doi: 10.1016/j.vaccine.2009.01.071. Epub 2009 Feb 5.
4
Alum adjuvanticity: unraveling a century old mystery.明矾佐剂活性：解开一个百年之谜。
Eur J Immunol. 2008 Aug;38(8):2068-71. doi: 10.1002/eji.200838648.
5
Targeting the nuclear antigen 1 of Epstein-Barr virus to the human endocytic receptor DEC-205 stimulates protective T-cell responses.将爱泼斯坦-巴尔病毒的核抗原1靶向人类内吞受体DEC-205可刺激保护性T细胞反应。
Blood. 2008 Aug 15;112(4):1231-9. doi: 10.1182/blood-2008-03-148072. Epub 2008 Jun 2.
6
The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine.微生物模拟物聚肌苷酸胞苷酸（poly IC）与一种靶向树突状细胞的疫苗共同诱导持久且具有保护性的CD4+ T细胞免疫。
Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2574-9. doi: 10.1073/pnas.0711976105. Epub 2008 Feb 6.
7
HMGB1 release induced by liver ischemia involves Toll-like receptor 4 dependent reactive oxygen species production and calcium-mediated signaling.肝脏缺血诱导的HMGB1释放涉及Toll样受体4依赖性活性氧生成和钙介导的信号传导。
J Exp Med. 2007 Nov 26;204(12):2913-23. doi: 10.1084/jem.20070247. Epub 2007 Nov 5.
8
Clinical setbacks for toll-like receptor 9 agonists in cancer.Toll样受体9激动剂在癌症治疗中的临床挫折
Nat Biotechnol. 2007 Aug;25(8):825-6. doi: 10.1038/nbt0807-825. Epub 2007 Aug 2.
9
CD40L - a multipotent molecule for tumor therapy.CD40L——一种用于肿瘤治疗的多能分子。
Endocr Metab Immune Disord Drug Targets. 2007 Mar;7(1):23-8. doi: 10.2174/187153007780059432.
10
DAMPs, PAMPs and alarmins: all we need to know about danger.损伤相关分子模式、病原体相关分子模式与警戒素：我们需要了解的有关危险的一切。
J Leukoc Biol. 2007 Jan;81(1):1-5. doi: 10.1189/jlb.0306164. Epub 2006 Oct 10.
Zotero 插件